Nassim Djebli

1.2k total citations
30 papers, 678 citations indexed

About

Nassim Djebli is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Nassim Djebli has authored 30 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pharmacology. Recurrent topics in Nassim Djebli's work include Drug Transport and Resistance Mechanisms (8 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Nassim Djebli is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Nassim Djebli collaborates with scholars based in France, Switzerland and United Kingdom. Nassim Djebli's co-authors include Pierre Marquet, Nicolas Picard, Jean-Philippe Rérolle, Yannick Le Meur, Thierry Cresteil, Guillaume Hoizey, David Fabre, Fabrice Hurbin, Sonia Khier and Jean-Christophe Szelag and has published in prestigious journals such as Blood, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Nassim Djebli

27 papers receiving 659 citations

Peers

Countries citing papers authored by Nassim Djebli

Since Specialization

Citations

This map shows the geographic impact of Nassim Djebli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nassim Djebli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nassim Djebli more than expected).

Fields of papers citing papers by Nassim Djebli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nassim Djebli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nassim Djebli. The network helps show where Nassim Djebli may publish in the future.

Co-authorship network of co-authors of Nassim Djebli

This figure shows the co-authorship network connecting the top 25 collaborators of Nassim Djebli. A scholar is included among the top collaborators of Nassim Djebli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nassim Djebli. Nassim Djebli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population pharmacokinetic modeling of dexmedetomidine nasal spray in Chinese adults 2025 ·Frontiers in Pharmacology ·Yuanyuan Huang, (unknown), Nassim Djebli, Hao Jiang, Guoping Yang	0
2	Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer 2024 ·CPT Pharmacometrics & Systems Pharmacology ·Peng R. Chen, Yanyan Zhang, Yike Wang, Ke Ma, (unknown), Nassim Djebli, Kai Shen	3
3	Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Nassim Djebli, Neil Parrott, (unknown), (unknown), Elena Guerini, David Carlile	7
4	Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors 2022 ·Cancer Chemotherapy and Pharmacology ·François Mercier, Nassim Djebli, (unknown), (unknown), Georgina Meneses‐Lorente	4
5	Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors 2021 ·Investigational New Drugs ·Georgina Meneses‐Lorente, Darren Bentley, Elena Guerini, Karey Kowalski, Edna Chow‐Maneval, Li Yu, Andreas Brink, Nassim Djebli, François Mercier, (unknown), Alex Phipps	26
6	Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making 2021 ·European Journal of Drug Metabolism and Pharmacokinetics ·Nassim Djebli, (unknown), Neil Parrott, Elena Guerini, Yumi Cleary, Stephen Fowler, Nicolas Frey, (unknown), François Mercier, Alex Phipps, Georgina Meneses‐Lorente	10
7	In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK) 2021 ·Investigational New Drugs ·Georgina Meneses‐Lorente, Stephen Fowler, Elena Guerini, Karey Kowalski, Edna Chow‐Maneval, Li Yu, François Mercier, Mohammed Ullah, Kenichi Umehara, Andreas Brink, (unknown), (unknown), Alex Phipps, Nassim Djebli	12
8	Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation 2021 ·European Journal of Drug Metabolism and Pharmacokinetics ·(unknown), Romaric Larcher, (unknown), Nassim Djebli, Sonia Khier	14
9	Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib 2020 ·The AAPS Journal ·Neil Parrott, Cordula Stillhart, Marc Lindenberg, Bjoern Wagner, Karey Kowalski, Elena Guerini, Nassim Djebli, Georgina Meneses‐Lorente	34
10	Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 2019 ·Blood ·Nassim Djebli, (unknown), (unknown), François Mercier, Nicole A. Kratochwil, Ann-Marie E Bröske, Natalie Dimier, Cristiano Ferlini, Tom Moore, Maja Weisser, Peter N. Morcos	7
11	Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II 2018 ·Clinical Pharmacokinetics ·(unknown), Nassim Djebli, (unknown), Aurélie Brunet, Fabrice Hurbin, (unknown), David Fabre	7
12	Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies 2017 ·Clinical Pharmacokinetics ·Nassim Djebli, (unknown), (unknown), Sonia Khier, Aurélie Brunet, Fabrice Hurbin, David Fabre	24
13	Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits 2016 ·European Journal of Drug Metabolism and Pharmacokinetics ·Nassim Djebli, Sonia Khier, (unknown), (unknown), (unknown), Gérard Fabre, Caroline Leriche, David Fabre	41
14	Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics 2015 ·Drug Metabolism and Disposition ·Nassim Djebli, David Fabre, Xavier Boulenc, Gérard Fabre, Eric Sultan, Fabrice Hurbin	38
15	Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite 2011 ·Drug Metabolism and Disposition ·Xavier Boulenc, Nassim Djebli, Juan Shi, Laurent Perrin, William R. Brian, Robert Van Horn, Fabrice Hurbin	34
16	Circadian Time‐Effect of Orally Administered Loratadine on Plasma Pharmacokinetics in Mice 2008 ·Chronobiology International ·(unknown), Mossadok Ben‐Attia, Mamane Sani, Nassim Djebli, (unknown), Naceur A. Boughattas	10
17	Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients 2007 ·Pharmacogenetics and Genomics ·Nassim Djebli, Nicolas Picard, Jean-Philippe Rérolle, Yannick Le Meur, Pierre Marquet	66
18	Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients 2006 ·Clinical Pharmacokinetics ·Nassim Djebli, Annick Rousseau, Guillaume Hoizey, Jean-Philippe Rérolle, Olivier Toupance, Yannick Le Meur, Pierre Marquet	67
19	CYP3A53 influences sirolimus oral clearance in de novo and stable renal transplant recipients 2006 ·Clinical Pharmacology & Therapeutics* ·Yannick Le Meur, Nassim Djebli, Jean-Christophe Szelag, Guillaume Hoizey, (unknown), Jean-Philippe Rérolle, Pierre Marquet	83
20	IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS 2005 ·Drug Metabolism and Disposition ·Nicolas Picard, Thierry Cresteil, Nassim Djebli, Pierre Marquet	112

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact